Page 132 - 《中国药房》2022年11期

e02243-16. et al. Synergistic activity of ceftazidime-avibactam and az-
[ 5 ] BIAGI M，WU T，LEE M，et al. Searching for the optimal treonam against serine and metallo-β-lactamase-producing
treatment for metallo- and serine-β-lactamase producing gram-negative pathogens[J]. Diagn Microbiol Infect Dis，
Enterobacteriaceae：aztreonam in combination with cef- 2017，88（4）：352-354.
tazidime-avibactam or meropenem-vaborbactam[J]. Anti- [15] GILBERT D N.桑福德抗微生物治疗指南[M]. 48版.范洪
microb Agents Chemother，2019，63（12）：e01426-19. 伟，译.北京：中国协和医科大学出版社，2019：86.
[ 6 ] FALCONE M，DAIKOS G L，TISEO G，et al. Efficacy of [16] 中国医药教育协会感染疾病专业委员会，中华医学会呼
ceftazidime-avibactam plus aztreonam in patients with 吸病学分会，中华医学会重症医学分会，等.中国多黏菌
bloodstream infections caused by metallo-β-lactamase- 素类抗菌药物临床合理应用多学科专家共识[J].中华结
producing Enterobacterales[J]. Clin Infect Dis，2021，72 核和呼吸杂志，2021，44（4）：292-310.
（11）：1871-1878. [17] DAVIDO B，FELLOUS L，LAWRENCE C，et al. Ceftazi-
[ 7 ] MOJICA M F，OUELLETTE C P，LEBER A，et al. Suc- dime-avibactam and aztreonam，an interesting strategy to
cessful treatment of bloodstream infection due to metallo- overcome β-lactam resistance conferred by metallo-β-lac-
β-lactamase-producing Stenotrophomonas maltophilia in tamases in Enterobacteriaceae and Pseudomonas aerugi-
a renal transplant patient[J]. Antimicrob Agents Chemother， nosa[J]. Antimicrob Agents Chemother，2017，61（9）：
2016，60（9）：5130-5134. e01008-e01017.
[ 8 ] BENCHETRIT L，MATHY V，ARMAND-LEFEVRE L， [18] LODISE T P，SMITH N M，O’DONNELL N，et al. Deter-
et al. Successful treatment of septic shock due to NDM-1- mining the optimal dosing of a novel combination regi-
producing Klebsiella pneumoniae using ceftazidime/avi- men of ceftazidime/avibactam with aztreonam against
bactam combined with aztreonam in solid organ transplant NDM-1-producing Enterobacteriaceae using a hollow-fi-
recipients：report of two cases[J]. Int J Antimicrob Agents， bre infection model[J]. J Antimicrob Chemother，2020，75
2020，55（1）：105842. （9）：2622-2632.
[ 9 ] TZOUVELEKIS LS，MARKOGIANNAKISA，PSICHOGIOU [19] BRADLEY J S，ROILIDES E，BROADHURST H，et al.
M，et al. Carbapenemases in Klebsiella pneumoniae and Safety and efficacy of ceftazidime-avibactam in the treat-
other Enterobacteriaceae：an evolving crisis of global di- ment of children ≥3 months to ＜18 years with compli-
mensions[J]. Clin Microbiol Rev，2012，25（4）：682-707. cated urinary tract infection：results from a phase 2 ran-
[10] 喻华，徐雪松，李敏，等.肠杆菌目细菌碳青霉烯酶的实验 domized，controlled trial[J]. Pediatr Infect Dis J，2019，38
室检测和临床报告规范专家共识[J].中国感染与化疗杂 （9）：920-928.
志，2020，20（6）：671-680. [20] BRADLEY J S，BROADHURST H，CHENG K R，et al.
[11] SHIELDS R K，NGUYEN M H，CHEN L，et al. Ceftazi- Safety and efficacy of ceftazidime-avibactam plus metro-
dime-avibactam is superior to other treatment regimens nidazole in the treatment of children ≥3 months to ＜18
against carbapenem-resistant Klebsiella pneumoniae bac- years with complicated intra-abdominal infection：results
teremia[J]. Antimicrob Agents Chemother，2017，61（8）： from a phase 2，randomized，controlled trial[J]. Pediatr In-
e00883-e00817. fect Dis J，2019，38（8）：816-824.
[12] TUMBARELLO M，TRECARICHI E M，CORONA A， [21] U.S. Food and Drug Administration. AVYCAZ prescri-
et al. Efficacy of ceftazidime-avibactam salvage therapy bing information[EB/OL].[2021-12-05]. https：//www.
in patients with infections caused by Klebsiella pneumoniae accessdata.fda.gov/drugsatfda_docs/label/2019/206494s005，
carbapenemase-producing K. pneumoniae[J]. Clin Infect s006lbl.pdf.
Dis，2019，68（3）：355-364. [22] STERNBACH N，LEIBOVICI WEISSMAN Y，AVNI T，
[13] POUCH S M，PATEL G，PRACTICE A S T I D C O. Mul- et al. Efficacy and safety of ceftazidime/avibactam：a sys-
tidrug-resistant Gram-negative bacterial infections in solid tematic review and meta-analysis[J]. J Antimicrob Che-
organ transplant recipients：Guidelines from the American mother，2018，73（8）：2021-2029.
Society of Transplantation Infectious Diseases Communi- （收稿时间：2022-01-06 修回时间：2022-03-30）
ty of Practice[J]. Clin Transplant，2019，33（9）：e13594. （编辑：刘明伟）
[14] WENZLER E，DERAEDT M F，HARRINGTON A T，

·1402 · China Pharmacy 2022 Vol. 33 No. 11 中国药房 2022年第33卷第11期